Amneal Pharmaceuticals is trading 5.5% up today at $19.32 after its July 30, 2026 earnings call highlighted a raised 2026 revenue outlook and a strategic pivot toward higher-margin specialty and biosimilars segments.
- The company announced the planned acquisition of Kashiv BioSciences, which management expects will establish biosimilars as a durable growth vertical.
- Investor sentiment is being driven by the shift toward higher-margin segments and the integration of new biosimilar assets to support long-term revenue growth.